Katherine Littrell | Head of IR |
Bruce Cozadd | Chairman and Chief Executive Officer |
Matthew Young | Executive Vice President and Chief Financial Officer |
Daniel Swisher | President and Chief Operating Officer |
Michael Miller | Executive Vice President, U.S. Commercial |
Allen Yang | Head of Clinical Development and Acting Chief Medical Officer |
Jed Black | Senior Vice President, Sleep and CNS Medicine |
Brandon Folkes | Cantor Fitzgerald |
Akash Tewari | Wolfe Research |
Umer Raffat | Evercore ISI |
Ronny Gal | Bernstein |
Gary Nachman | BMO Capital Markets |
David Amsellem | Piper Jaffray |
Jason Gerberry | Bank of America |
Annabel Samimy | Stifel |
David Risinger | Morgan Stanley |
Jessica Fye | JPMorgan |
Welcome to the Jazz Pharmaceuticals Plc Fourth Quarter and Full Year 2018 Earnings Conference Call.
Following an introduction from the company, we'll open the call to questions. I will now turn the call over to Katherine Littrell, Head of Investor Relations at Jazz Pharmaceuticals.
Thank you, Dolan. And thanks to those of you joining our investor call today.